Results of interval debulking surgery in advanced stage ovarian cancer: An exposed-non-exposed study

Annals of Oncology

Volumn 14, Issue 1, 2003, Pages 74-77

  Morice, P ^a   Brehier Ollive, D ^a   Rey, A ^a   Atallah, D ^a   Lhomme C ^a   Pautier, P ^a   Pomel, C ^a   Camatte, S ^a   Duvillard, P ^a   Castaigne, D ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Induction chemotherapy; Interval debulking surgery; Ovarian cancer; Unresectable tumour

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TRANSFUSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; HYSTERECTOMY; INTERMETHOD COMPARISON; INTERVAL DEBULKING SURGERY; LYMPHADENECTOMY; MORBIDITY; MORTALITY; OVARY CANCER; PRIMARY DEBULKING SURGERY; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; SURGICAL TECHNIQUE;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, ENDOMETRIOID; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; CYSTADENOCARCINOMA, SEROUS; FEMALE; HOSPITALIZATION; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; OVARIECTOMY; POSTOPERATIVE COMPLICATIONS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 12244305147     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg003     Document Type: Article

References (25)

1. Griffiths TC, Parker LM, Fuller AF. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 1979; 63: 235-240.
2. Michel G, De Iaco P, Castaigne D et al. Extensive cytoreductive surgery in advanced ovarian carcinoma. Eur J Gynaec Oncol 1997; 18: 9-15.
3. Hacker NF, Berek JS, Lagasse LD et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983; 61: 413-420.
4. Hoskins WJ, McGuire WP, Brady MF et al. The effect of the diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994; 170: 974-980.
5. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 1998; 69: 103-108.
6. Guidozzi F, Ball JH. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 1994; 53: 326-330.
7. Shimada M, Kigawa J, Minagawa Y et al. Significance of cytoreductive surgery including bowel resection for patients with advanced ovarian cancer. Am J Clin Oncol 1999; 22: 481-484.
8. Donato D, Angelides A, Irani H et al. Infectious complications after gastrointestinal surgery in patients with ovarian carcinoma and malignant ascites. Gynecol Oncol 1992; 44: 40-47.
9. Vergote IB, De Wever I, Decloedt J et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 1998; 71: 431-436.
10. Lawton FG, Redman CW, Luesley DM et al. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced epithelial ovarian cancer. Obstet Gynecol 1989; 73: 61-65.
11. Chambers JT, Chambers SK, Voynick IM, Schwartz PE. Neoadjuvant chemotherapy in stage X ovarian carcinoma. Gynecol Oncol 1990; 37: 327-331.
12. Jacob JH, Gershenson DM, Morris M et al. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol 1991; 42: 146-150.
13. Lim JTW, Green JA. Neoadjuvant carboplatin and ifisfamide chemotherapy in inoperable FIGO stage III and IV ovarian carcinoma. Clin Oncol 1993; 5: 198-202.
14. Surwit E, Childers J, Atlas I et al. Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer 1996; 6: 356-361.
15. Schwartz PE, Rutherford TJ, Chambers JT et al. Neoadjuvant chemotherapy for advanced ovarian cancer: Long-term survival. Gynecol Oncol 1999; 72: 93-99.
16. Kayikcioglu LF, Kose MF, Boran N et al. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 2001; 11: 466-470.
17. Kuhn W, Rutke S, Spathe K et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 2001; 92: 2585-2591.
18. Ansquer Y, Leblanc E, Clough K et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma. Cancer 2001; 1: 2329-2334.
19. Redman CW, Warwick J, Luesley DM et al. Intervention debulking surgery in advanced epithelial ovarian cancer. Br J Obstet Gynaecol 1994; 101: 142-146.
20. Van der Burg ME, Van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995; 332: 629-634.
21. Mc Guire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
22. Colombo N, ICON Collaborators. Randomized trial of paclitaxel (PTX) and carboplatin (CBDCA) versus a control arm of carboplatin or CAP (cyclophosphamide, doxorubicin and cisplatin): the Third International Collaborative Ovarian Neoplasm Study (ICON 3). Proc Am Soc Clin Oncol 2000; 19: 1500.
23. Morice P, Viala J, Pautier P et al. Port site metastasis after laparoscopic surgery for gynecological cancer. Report of 6 cases and surgical implications for prevention. J Reprod Med 2000; 45: 837-840.
24. Vergote IB, De Wever I, Decloedt J et al. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Semin Oncol 2000; 27: 31-36.
25. Van Dam PA, DeCloedt J, Tjalma WA et al. Trocar implantation metastasis after laparoscopy in patients with advanced ovarian cancer: can the risk be reduced? Am J Obstet Gynecol 1999; 181: 536-541.